Mental Health Clinics in Wayne, NE Accepting Medicare
7 Mental Health Clinics found. Showing 1 - 7
 Advance Counseling Services, Llc Counselor Medicare: Medicare Enrolled Practice Location: 220 W 7th St, Suite 1, Wayne, NE 68787 Phone: 402-833-5246 Fax: 402-833-5283 |
Prairie Psychological Services, Inc Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 219 Main St, Ste 2, Wayne, NE 68787 Phone: 402-494-0040 |
Cmhwc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 219 Main St, Wayne, NE 68787 Phone: 402-375-5741 Fax: 402-375-3879 |
Heartland Counseling Services.inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 112 E 2nd St, Ste. 115, Wayne, NE 68787 Phone: 402-494-3337 |
Pearl Street Counseling, Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 421 N Pearl Street, Wayne, NE 68787 Phone: 402-286-4891 |
Grace Counseling Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 111 Main Street, Wayne, NE 68787 Phone: 402-518-0490 |
Paula M Peterson Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 803 Providence Rd, Suite 102, Wayne, NE 68787 Phone: 402-833-1410 |
News Archive
Researchers show that Sirt3 enzyme decreases in skeletal muscle of diabetes patients
Researchers at the Joslin Diabetes Center have shown that an enzyme found in the mitochondria of cells is decreased in the skeletal muscle of those with diabetes, a finding that could lead to the development of drugs to boost the activity of this enzyme in an effort to fight the disease.
G-CON completes delivery and installation of POD system in PaxVax's GMP production facility
G-CON today announced the completed delivery and installation of the ground-breaking POD system in PaxVax's licensed GMP production facility based in San Diego, California where PaxVax manufactures innovative and socially responsible oral vaccines against infectious diseases.
Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma
Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.
Findings reveal potential drug targets for small cell lung cancer
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
› Verified 7 days ago